HS235
Pulmonary Arterial Hypertension, PH‑HFpEF
Phase 1/2Active
Key Facts
About 35Pharma
35Pharma creates multi‑specific Activin/GDF ligand traps to treat high‑unmet‑need cardiometabolic and pulmonary diseases.
View full company profilePulmonary Arterial Hypertension, PH‑HFpEF
35Pharma creates multi‑specific Activin/GDF ligand traps to treat high‑unmet‑need cardiometabolic and pulmonary diseases.
View full company profile